Lifevantage (LFVN) Earnings Date & Reports

Key Takeaways

• LifeVantage reported first-quarter fiscal 2027 net revenue of $37.1 million, down 22% from $47.6 million a year earlier.
• Adjusted earnings per share (EPS) came in at $0.05, below the consensus estimate of $0.08, while revenue also missed the roughly $41.45 million analysts expected.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) fell to $1.9 million, or 5.2% of revenue, from $3.9 million in the prior-year period.
• The company swung to a GAAP (Generally Accepted Accounting Principles) net loss of $0.2 million, or $0.02 per diluted share, versus net income of $2.2 million a year ago.
• Softer order volumes, smaller average order size, and weaker MindBody GLP-1 System sales drove the decline, partially offset by the LoveBiome product line acquired in October 2025.
• LifeVantage ended the quarter with $13.7 million in cash and no debt outstanding.
• For additional context on LFVN's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
• You can also discover automated trading ideas by exploring Tickeron's Trending AI Robots.

Earnings Context and Why It Matters

LifeVantage Corporation is a health and wellness company best known for its Protandim product line and, more recently, its MindBody GLP-1 System, which targets the glucagon-like peptide-1 (GLP-1) pathway tied to appetite and metabolism. This quarterly report carries extra weight because it is the first since the company began transitioning its fiscal year and since new leadership outlined a strategic reset. Investors are closely watching whether the LoveBiome acquisition can offset persistent demand softness in the core direct-selling business and whether a declining active-account base can stabilize. With subscription revenue still representing more than 75% of the total, the durability of that recurring base remains a central focus of the story.

Reported Results

For the first quarter of fiscal 2027, ended September 30, 2026, LifeVantage reported net revenue of $37.1 million, a 22% decline from $47.6 million in the prior-year period. Revenue in the Americas fell 22.2% to $29.0 million, while the Asia-Pacific and Europe region declined 21.2% to $8.2 million, including a $0.4 million negative foreign-currency impact.

GAAP net loss was $0.2 million, or $0.02 per diluted share, compared with net income of $2.2 million, or $0.17 per diluted share, a year earlier. Adjusted non-GAAP net income was $0.6 million, or $0.05 per diluted share, down from $2.3 million, or $0.18 per diluted share. Both revenue and adjusted EPS fell short of consensus estimates of roughly $41.45 million and $0.08, respectively.

Gross profit margin declined to 75.4% from 79.5%, reflecting higher inventory obsolescence expenses and elevated shipping and warehouse costs; excluding the MindBody-related inventory allowance, adjusted gross margin was 78.2%. Adjusted EBITDA was $1.9 million, or 5.2% of revenue, compared with $3.9 million, or 8.2%, a year ago. Management attributed the weakness primarily to lower order volumes, reduced average order size, and continued softness in MindBody GLP-1 System sales, partly offset by LoveBiome contributions.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and broader market opportunities more efficiently than manual screening. For investors tracking names like LifeVantage, it offers a structured way to monitor shifts in momentum and fundamentals alongside AI-generated signals. Explore the AI Screener to see how it can refine your research workflow.

Market Reaction and Investor Sentiment

The market responded negatively to the results. Shares fell roughly 5.5% in after-hours trading to near $5.00 following the release, reflecting disappointment that both revenue and adjusted EPS missed analyst expectations. The stock had already been under pressure, declining about 14% year to date ahead of the report. Investor sentiment remains cautious as the company works through a leadership transition and a reset of its product and brand strategy. The combination of a shrinking active-account base, macro-driven pressure on consumer spending, and difficult year-over-year comparisons for the MindBody GLP-1 System has kept confidence subdued, even as the balance sheet remains debt-free and the recurring subscription mix stays above 75% of revenue.

Forward Outlook and Key Factors to Monitor

Looking ahead, several factors will shape LifeVantage's trajectory. First, the company is managing a fiscal-year transition, with an anticipated effective tax rate of approximately 20% to 25% for the six-month period ending December 31, 2026. This shift adds a layer of complexity to year-over-year comparisons that investors should keep in mind.

Second, the LoveBiome integration remains a key swing factor. Management has highlighted early momentum in the microbiome health business, but its ability to offset declines in the legacy product portfolio will be central to any revenue stabilization. The MindBody GLP-1 System also faces tough prior-year comparables and a competitive wellness landscape.

Finally, watch for progress on the operational reset outlined by leadership, including a review of selling, general, and administrative (SG&A) expenses, investment in a new e-commerce platform, and efforts to improve consultant and customer retention. A debt-free balance sheet with $13.7 million in cash and a $60 million share repurchase authorization provides financial flexibility, but sustained demand recovery will ultimately determine whether the business can return to growth in the back half of the fiscal year.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations